ro 22-1319 has been researched along with Tourette Syndrome in 3 studies
*Tourette Syndrome: A neuropsychological disorder related to alterations in DOPAMINE metabolism and neurotransmission involving frontal-subcortical neuronal circuits. Both multiple motor and one or more vocal tics need to be present with TICS occurring many times a day, nearly daily, over a period of more than one year. The onset is before age 18 and the disturbance is not due to direct physiological effects of a substance or another medical condition. The disturbance causes marked distress or significant impairment in social, occupational, or other important areas of functioning. (From DSM-IV, 1994; Neurol Clin 1997 May;15(2):357-79) [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, PA; Pruitt, B; Stahl, SM; Uhr, SB | 3 |
2 trial(s) available for ro 22-1319 and Tourette Syndrome
| Article | Year |
|---|---|
Case report of four patients with Tourette syndrome treated with piquindone, a D2 receptor antagonist.
Topics: Adolescent; Adult; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Tourette Syndrome | 1986 |
Improvement of symptoms in Tourette syndrome by piquindone, a novel dopamine-2 receptor antagonist.
Topics: Adult; Clinical Trials as Topic; Dopamine Antagonists; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Receptors, Dopamine; Tourette Syndrome | 1986 |
1 other study(ies) available for ro 22-1319 and Tourette Syndrome
| Article | Year |
|---|---|
Treatment of Tourette's syndrome with RO22-1319, a D-2-receptor antagonist.
Topics: Adolescent; Antipsychotic Agents; Humans; Isoquinolines; Male; Receptors, Dopamine; Receptors, Dopamine D2; Tourette Syndrome | 1984 |